Immunovant, Inc. Common Stock

Go to Immunovant, Inc. Common Stock Website

$30.70

(%)
Live
Previous Close

$30.7

Day Range

$ - $

Previous Day Range

$ - $

Market Cap

$4.5 billion USD

Day Vol.

Previous Day Vol.

Currency

USD

Primary Exchange

Nasdaq

Immunovant Inc is a clinical-stage biopharmaceutical company. It is focused on enabling normal lives for patients with autoimmune diseases. The company's product includes batoclimab and IMVT-1402 targets the neonatal Fc receptor (FcRn)....


Community
  • 0 posts discussing
0

Watchers

0

Visitors


Recent News

The average of price targets set by Wall Street analysts indicates a potential upside of 68.6% in Immunovant (IMVT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Related tickers: IMVT.

Read Full Article

BioMarin, Blueprint Medicines, Immunovant, Kymera and Ligand have been highlighted in this Industry Outlook article.

Related tickers: BMRN, LGND, BPMC, IMVT, KYMR.

Read Full Article
Trending Tickers
CTMX

XNAS

$1.89
(%)
MIMO

XASE

$0.11
(%)
PRSO

XNAS

$1.38
(%)
QQQ

XNAS

$451.76
(%)
$0.00
(%)